Orchard Therapeutics plc
ORTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -13.8% | 491.3% | -82.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.3% | 70.1% | 70.3% | 127.3% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -549.4% | -266.8% | -1,590.6% | 1,915.2% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -560.4% | -168.3% | -1,407.6% | 1,930.9% |
| EPS Diluted | -1.55 | -0.65 | -1.23 | 10.52 |
| % Growth | -138.5% | 47.2% | -111.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |